Τόμος 20 (2002) – Τεύχος 1 – Άρθρο 6 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 20 (2002) – Issue 1 – Article 6 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Από | | Άρθρο - Article, Ελένη Κίντζιου - Helen Kintziou, Ελένη Πλέσσα - Helen Plessa, Ευαγγελία Πρωτόπαπα - Evangelia Protopapa, Νικόλαος Σταυριανέας,Nicolas Stavri­aneas, Πλήρες Κείμενο στα Ελληνικά - Full Text in Greek, Χρίστος Π. Τσαχαγέας,Christos P. Tsachageas

 

Τίτλος – Title

Ηλιακή Ακτινοβολία, Βλάβη DNA και Καρκίνος Δέρματος: Σύντομη Θεώρηση

Sunlight, DNA Damage and Skin Cancer: A short View
Συγγραφέας – Author

Ελένη Κίντζιου1, Ευαγγελία Πρωτόπαπα1, Χρίστος Π. Τσαχαγέας1, Νικόλαος Σταυριανέας2, Ελένη Πλέσσα3

1 Τμήμα Αισθητικής, Τεχνολογικό Εκπαιδευτικό Ίδρυμα Αθήνας, Αθήνα, Ελλάς 2 Εργαστήριο Δερματολογίας, Ιατρική Σχολή, Πανεπιστήμιο Αθηνών, Αθήνα, Ελλάς 3 Τμήμα Επιστημονικής Ενημέρωσης του ΦΑΡΜΑΚΟΝ-Τύπος, Αθήνα, Ελλάς

Helen Kintziou1, Evangelia Protopapa1, Christos P. Tsachageas1, Nicolas Stavri­aneas2, Helen Plessa3

1 Technological Educational Institution of Ath­ens, Egaleo, Athens, Greece 2 Department of Dermatology, Medical School, University of Athens, Syggrou Hospital, Athens, Greece 3 PHARMAKON-Press Information Services, Athens, Greece
Παραπομπή – Citation

Κίντζιου,Ε., Πρωτόπαπα,Ε., Τσαχαγέας,Χ.Π., Σταυριανέας,Ν., Πλέσσα,Ε. : Ηλιακή Ακτινοβολία, Βλάβη DNA και Καρκίνος Δέρματος: Σύντομη Θεώρηση, Επιθεώρηση Κλιν. Φαρμακολ. Φαρμακοκινητ. 20: 45-52 (2002)

Kintziou,H., Protopapa,E., Tsachageas,Ch.P., Stavri­aneas,N., Plessa,H. : Sunlight, DNA Damage and Skin Cancer: A short View, Epitheorese Klin. Farmakol. Farmakokinet. 20: 45-52 (2002)
Ημερομηνία Δημοσιευσης – Publication Date
1 Μαρτίου 2002 – 2002-03-01
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Ελληνικά – Greek
Παραγγελία – Αγορά –
Order – Buy
Ηλεκτρονική Μορφή: pdf (15 €) –
Digital Type: pdf (15 €)
pharmakonpress[at]pharmakonpress[.]gr
Λέξεις κλειδιά – Keywords
Ηλιακή ακτινοβολία, βλάβη DNA, καρκίνος δέρματος, αντιηλιακά
Sunlight, DNA damage, skin cancer, sunscreens
Λοιποί Όροι – Other Terms

Άρθρο

Article
Περίληψη – Summary

Η ηλιακή ακτινοβολία είναι μορφή ενεργείας χαρακτηριζόμενη από το μήκος κύματός της. Τη Δερματολογία ενδιαφέρουν οι περιοχές της υπεριώδους ακτινοβολίας (UVC 200-2900 nm, UVB 290-320 nm και UVA 320-400 nm) και το ορατό φως (400-800 nm). H UVC απορροφείται από τη στοιβάδα όζοντος της ατμοσφαίρας και δεν φθάνει την επιφάνεια της γης. Η UVB, η πλέον ερυθηματογόνος και μελανινογόνος ακτινοβολία, προκαλεί ηλιακά εγκαύματα, ηλιοκαμένο δέρμα, καρκίνο δέρματος και φωτογήρανση. Η UVA είναι 1000 φορές ολιγότερο ερυθηματογόνος από ό,τι η UVB. Όμως, αυτή εισχωρεί βαθύτερα, συμβάλλει σε φωτογήρανση και σε φωτοευαίσθητες νόσους, ενισχύει το ερύθημα που επάγεται από την UVB και αυξάνει τον κίνδυνο για επαγωγή καρκινογένεσης. Η ορατή ακτινοβολία ευθύνεται για περιπτωσιακά φωτοευαίσθητα εξανθήματα. Στις οξείες δράσεις της έκθεσης στον ήλιο περιλαμβάνονται εγκαύματα, ανάπτυξη νέων εξανθημάτων, επιδείνωση παλαιών και επαγωγή φωτοτοξικών αντιδράσεων από φάρμακα. Στις χρόνιες δράσεις περιλαμβάνονται υπερχρωματισμός του δέρματος, εκφύλιση του κολλαγόνου και νεοπλασία. Το μήκος κύματος της ακτινοβολίας για ορισμένες νόσους είναι σχεδόν τελείως καθορισμένο και μπορεί να έχει σημαντικές διαγνωστικές και θεραπευτικές συνέπειες. Στην αγορά διατίθενται ορισμένα αντιηλιακά παρασκευάσματα που παρέχουν κάποιου βαθμού προστασία και βοηθούν το μαύρισμα του δέρματος, αλλά δεν προλαμβάνουν πλήρως το ηλιακό έγκαυμα.

Solar radiation is defined in terms of wavelength. Dermatologists are most concerned with the regions of ultraviolet radiation (UVC, 200 to 290 nm; UVB, 290 to 320 nm; and UVA 320 to 400 nm) and with visible radiation (400 to 800 nm). UVC is absorbed by the ozone layer and does not reach the earth’s surface. UVB, the most erythrogenic and melanogenic type of ra­diation, causes sunburn, suntan, skin cancer and photoaging. The longer wavelengths of UVA are 1000 times less erythrogenic than UNB. How­ever, they penetrate more deeply and contribute to photoaging and photosensitivity diseases; the also enhance UNB-induced erythema and in­crease the risk of UVB-induced carcinogenesis. Visible radiation is responsible for occasional photosensitive eruptions. Acute effects of sun exposure include sunburn, the development of new rashes, the exacerbation of existing rashes and drug-induced phototoxic reactions; the chronic ones are hyperpigmentation, collagen degeneration and neoplasia. The wavelength responsible for some diseases is quite specific and can have important diagnostic and therapeu­tic consequences. A number of sunscreen prepa­rations are available which do give some protec­tion and aid tanning but they do not prevent com­pletely burning in the susceptible. Despite its side effects, non­ionizing electromagnetic radia­tion is employed therapeutically.

Αναφορές – References
 1. Πλέσσας Σ.Τ., Σουλιώτη Ε., Πλέσσας Χ.Τ.: Δεσοξυριβονουκλεϊνικά οξέα – DNA: Χρήσεις τους στην Κοσμετολογία και στη Θεραπευτική. Επιθεωρ. Κλιν. Φαρμακολ. Φαρμακοκινετ. 3: 130-136 (1985)

2. McCollum E., et al.: Studies on experimental tickets. J. Biol. Chem. 53: 292-312 (1922)

3. Molonowski W.: Ledrgej Suiadecki (1768-1883) on the cure tickets. Nature (London) 143: 121 (1939)

4. Studginski G.P., Mooze D.C.: Sunlight – Can it prevent as well as cause cancer? Cancer Res. 55: 4014-4022 (1995)

5. Gorham E.D., et al.: Acid hage air pollution and breast and solon cancer mortality in 20 Canadian cities. Can. J. Publ. Health 80: 96-100 (1989)

6. Garland C., et al.: Geographic variation in breast cancer mortality in the United States: a hypothesis involving expo­sure to solar radiation. Prev. Med. 19: 614-622 (1990)

7. Garland C., et al.: Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2: 1176-1178 (1989)

8. Hachette C.L., Schwartj G.C.: Gographic pattery of prostate cancermortality. Cancer (Phila.) 70: 2861-2869 (1992)

9. ColstonK.W., et al. : EBIO 89, a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 44: 2273-2280 (1992)

10. Cross H.S., et al.: Antiproliferative effect of 1,25-dihy­droxyvitamin D3 and its analogs on human colon adeno­carcinoma cells: influence of extracellular calcium. Bio­chem. Biophys. Res. Commun. 179: 57-62 (1991)

11. Moller G.J., et al.: The human prostatic carcinoma cell line LNCal expresses biologically active, specific receptors for 1a.25-dihydroxyvitamin D3: Cancer Res. 52: 515-520 (1992)

12. Skowronski R.J., et al.: Vitamin D and prostate cancer. 1,25dihydroxyvitamin D receptors and actions in human prostate cancer lines. Endocrinology 132: 1952-1960 (1991)

13. Peehl D.M., et al.: Antiproliferative effects of 1,25-dihy­droxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 54: 805-820 (1994)

14. Beaty M.M., et al.: Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2in-dimwthyldrajine-induced colon carcinogenesis in rats get high fat diets. J. Natr. 123: 144-152 (1993)

15. Plummer M.A., et al.: Inflammation in human skin is induced by ultraviolet irradiation. Postgrad. Med. J. 53: 656-657 (1977)

16. Hruja L.L., Pentland A.P.: Mechanisms of W-induced inflammation. J. Invest. Dermatol. 100(Suppl.): 355-415 (1993)

17. Andersen P.H., et al.: A time-correlation study of ultra­violet B-induced erythema measured by reflectance spec­troscopy and laser Doppler flowmetry. Photodermatol. Photomed. 8: 123-128 (1991)

18. Kligman A.M., Lavker R.M.: Cutaneous aging: the dif­ferences between intrinsic aging and photoaging. J. Cutan. Aging Cosmet. Dermatol. 1: 5-12 (1988)

19. Taylor C.R., et al. : Photoaging/photodamage and photoprotection. J. Am. Acad. Dermatol. 22: 1-15 (1990)

20. Gilhrest B.A., Yaar M.: Ageing and photoageing of the skin.: observations at the cellular and molecular level. Br. J. Dermatol. 127 (Suppl. 41): 25-30 (1992)

21. Kefala V., Protopapa E.E., Plessas S.T.: Photoaging: An esthetic problem. Prevention or treatment? Epitheor. Klin. Farmakol. Farmakokinet., International Edition 15: 33-42 (2001)

22. Kefala V., Protopapa E.E., Plessas S.T.: The use of chemical peeling in the management of esthetic problems deriving from skin diseases. Epitheor. Klin. Farmakol. Far­makokinet., International Edition 15: 5-14 (2001)

23. Cascinelli N. Mascinelli R.: Increasing incidence of cutaneous melanoma, ultraviolet radiation and the clinician. Photochem. Photobiol. 50: 497-505 (1989)

24. Green A., et al.: Sunburn and malignant melanoma. Br. J. Cancer 51: 393-397 (1985)

25. Mackie R.M., et al. : Personal risk-factor chart for cuta­neous melanoma. Lancet 2: 487-490 (1989)

26. Gellin G.A., e al.: Basal cell epitheliomas. A controlled study of associated factors. Arch. Dermatol. 91: 38-45 (1965)

27. Hogan D.J., et al.: Risk factors for squamous cell carci­noma of the skin. J. Dermatol. Sci. 1: 97-100 (1990)

28. Zanetti R., et al.: The multicenter South European Study HELIOS I : Skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin. Br. J. Cancer 73: 1440-1446 (1996)

29α. Ανθούλη-Αναγνωστοπούλου Φ., Κανέλλος Ε., Χατξηόλου Ε., Σταυριανέας Ν., Σουλιώτη Ε., Σοπίδου Β., και συν.: Συμπεριφορά ινοσκληρυντικού (Morphea-like)  βασικοκυτταρικού καρκίνου του δέρματος. Υπάρχει ασφαλής θεραπευτική αντιμετώπιση; Επιθ. Κλιν. Φαρμακολ. Φαρμακοκινητ. 18: 181-190 (2000)

29. Elwood M.J.: Melanoma and sun exposure. Seminars in Oncology 23: 650-666 (1996)

30. Elwood M.J., et al.: Cutaneous melanoma in relationto intermittent and constant sun exposure. Int. J. Cancer 35: 427-433 (1985)

31. Garbe C., et al.: Markers and relative risk in a German population for developing malignant melanoma. Int. J. Dermatol. 28: 517-523 (1989)

32. Whiteman D., Green A.: Melanoma and sunburn. Can­cer Causes Control 5: 564-572 (1994)

33. Katsambas A., Nicolaidou E.: Cutaneous Malignant melanoma and sun exposure. Arch. Dermatol. 132: 444-450 (1996)

34. Holman L.D., et al.: A theory of the etiology and patho­genesis of human cutaneous malignant melanoma. J. Natl. Cancer Inst. 71: 651-656 (1983)

35. Gutman M., et al.: Malignant melanoma in different ethnic groups in Israel. Incidence and biologic behaviour. Cancer 71: 2746-2750 (1993)

36. Klepp O., Magnus K.: Some environmental and bodily characteristics of melanoma patients. A case-control study. Int. J. Cancer 23: 482-486 (1979)

37. Streetly A., Markowe H.: Changing trends in the epide­miology of malignant melanoma: gender differences and their implications for public health. Int H. Epidemiol. 24: 897-907 (1995)

38. Elder D.E.: Skin cancer. Cancer 75: 245-256 (1995)

39. Popesan N.A., et al.: Cutaneous malignant melanoma in Rochester, Minnesota: trends in incidence and survivor­ship. Mayo Clin. Proc. 65: 1293-1302 (1990)

40. Rigel D.S., et al.: The incidence of malignant melanoma in the United States: issues as we approach the 21st cen­tury, J. Am. Acad. Dermatol. 34: 839-847 (1996)

41. Beadle P.C., et al.: Accuracy of skin cancer incidence data in the United Kingdom. Clin. Exp. Dermatol. 7: 255-260 (1982)

42. Giles G.G., et al.: Incidence of non-melacytic skin can­cer treated in Australia. Br. Med, J. 296: 13-17 (1988)

43. Marks R., et al.: Trends in non-melanocytic skin cancer treated in Australia. The second national survey. Int. J. Cancer 53: 585-590 (1993)

43α. Anthouli-Anagnostopoulou F.A., Kanellos E., Hatziolou E., et al.: Morpheaform basal cell carcinoma of the skin. A difficult to treat type of basal cell carcinoma. Histopa­thological study of 759 cases and review of the literature. Epitheor. Klin. Farmakol. Farmakokinet., International Edi­tion 15: 43-49 (2001)

43b. Anthouli-Anagnostopoulou F.A.: Prognostic factors in Morphean basal cell carcinoma of the skin. A clinicopathological study of 104 cases and review of the literature. Epitheor. Klin. Farmakol. Farmakokinet., International Edi­tion 15: 211-218 (2001)

44. Gallagher R.P., et al.: Sunlight exposure, pigmentary factors and risk of non-melanocytic skin cancer. Arch. Der­matol. 131: 157-163 (1995)

45. Kricker A., et al.: Does intermittent sun exposure cancer basal cell carcinoma? Int. J. Cancer 60: 489-494 (1995)

46. Weinstock M.A. : Epidemiologic investigation of non melanoma skin cancer mortality. J. Invest. Dermatol. 102: 6S-9S (1994)

47. Kraemer K.H.: Sunlight and skin cancer: Another link revealed. Proc. Natl. Acad. Sci. (USA) 94: 11-14 (1997)

48. Harvey I., et al.: Non-melanoma skin cancer and solar keratoses. I: Methods and descriptive results of the South Wales skin cancer study. Br. J. Cancer 74: 1302-1307 (1996)

49. Harvey I., et al.: Non-melanoma skin cancer and solar keratoses. II: Methods and descriptive results of the South Wales skin cancer study. Br. J. Cancer 74: 1308-1312 (1996)

50. Trouton K.J.: A place in the shade: reducing the risk of UV exposure. Can. Med. Ass. J. 157: 175-176 (1997)

51. Tucker A., et al. : Clinical recognised dysplastic nevi: a central risk factor for cutaneous melanoma. J.A.M.A. 277: 1439-1444 (1997)

52. Leffell D.J., Brash D.E.: Sunlight and skin cancer . Scientific American July: 38-43 (1996)

53. Weinstock M.A.: Controversies in the role of sunlight in the pathogenesis of cutaneous melanoma. Photochem. Photobiol. 63: 406-410 (1996)

54. Elwood J.M.: Screening for melanoma and options for its evaluation. J. Med. Screen 1: 22-38 (1994)

55. Spencer J.M., Amonette R.A.: Indoor tanning: risks, benefits and future trends. J. Am. Acad. Dermatol. 33: 288-298 (1995)

56. Guzzo C.A., Lazarus G.S., Werth V.P.: Dermatological Pharmacology. In: (Hardman J.G, Limbird L.E., eds) Goodman’s and Gilman’s The Pharmacological Basis of Therapeutics. Pp. 1593-1616, Ninth Edition, McGraw-Hill, New York, 1996

57. Kefala V., Kostara I., Karageorgiou H., Varonos D.D.: In vitro model for the evaluation of sunscreen agents pho­totoxic activity. Epitheor. Klin. Farmakol. Farmakokinet., International Edition 12: 59-62 (1998)

58. Kefala V., Kostara I., Karageorgiou H., Varonos D.D.: In vitro model for the evaluation of essential oils materials phototoxic activity. Epitheor. Klin. Farmakol. Farmakokinet., International Edition 12: 53-57 (1998)

59. Kefala V., Kostara I., Karageorgiou H., Varonos D.D.: In vitro model for the evaluation of medicinals phototoxic activity. Epitheor. Klin. Farmakol. Farmakokinet., Interna­tional Edition 14: 43-47 (2000)

60. Kefala V., Kostara I., Karageorgiou H., Varonos D.D.: In vitro model for the evaluation of preservatives phototoxic activity. Epitheor. Klin. Farmakol. Farmakokinet., Interna­tional Edition 14: 93-96 (2000)

61. Naylor M.F.: High sun protectio facto (SPF) sunscreens in the suppression of actinic neoplasias. Care Cure 4: 7-8 (1996)

62. Naylor M.F.: Erythema, skin cancer risk and sun­screens. Arch. Dermatol. 133: 373-375 (1997)

63. Whimore S.E., Morison W.L.: Protection of UVB-in­duced immunosupperssion in humans by a high sun pro­tection factor sunscreen. Arch. Dermatol. 131: 1128-1133 (1995)

64. World Health Organization: Protection against exposure to ultraviolet radiation. Geneva Intersun, WHO/EHG/95.17 UNEP, 1995

65. McGregor J.M., Young A.R.: Sunscreens, suntans and skin cancer. Br. Med. J. 312: 1621-1622 (1996)

66. Autier P., et al.: Melanoma and use of sunscreens: an EORTC case control study in Germany, Belgium and France. Int. J. Cancer 61: 749-755 (1995)

67. Naylor M.F., et al.: The case of sunscreens. Arch. Der­matol. 133: 1146-1154 (1997)

68. Stern R.S.: Sunscreens for skin cancer prevention. Arch. Dermatol. 131: 220-221 (1995)

69. Bergfeld W.F., et al.: Executive summary of the Na­tional Partners in Prevention Skin Cancer Conference. J. Am. Acad. Dermatol. 36: 798-801 (1997)

70. Sunsmart evaluation studies No 4. The Anticancer Council’s skin cancer control program. 1995 ISSN 1033-1442

71. Koh H., et al.: Sunbathing habits and sunscreen use among white adults: Results of a National Survey. Am. J. Publ. Health 87: 1214-1217 (1997)

72. Hall H.I., et al.: Sun protection behavior of the U.S. White population. Prev. Med. 26: 401-407 (1997)

73. Diffey .L.: People do not apply enough sunscreen for protection. Br. Med. J. 313: 942 (1996)

74. Fleming C., Mackie R.: Knowledge about sunscreens is in adequate. Br. Med. J. 313: 942 (1996)

75. Rosso S., et al.: The multicenter South European study HELIOS II: Different sun exposure patterns in the aetiology of basal call and squamous cell carcinomas of the skin. Br. J. Cancer 73: 1447-1454 (1996)

76. Hughes B.R., et al.: Health education about sun and skin cancer. A.A.D. annual meeting, 1996

77. Goldsmith M.F.: A.A.D. wants to covert sun worshipers. J.A.M.A. 277: 174501746 (1997)

78. MMWR: Media Dissemination of and Public Response to the ultraviolet Index-United States 1994-95. J.A.M.A. 277: 1751-1752 (1997)

79. Diffey B.L., Grice J.: The influence of sunscreen type on photoprotection. Br. J. Dermatol. 137: 103-105 (1997)

80. Robinson J.K., et al. Summer sun exposure: knowl­edge, attitudes and behaviors of Midwest adolescents. Prev. Med. 26: 365-372 (1997)

81. Robinson J.K., et al.: Trends in sun exposure: knowl­edge, attitudes and behaviours 1986 to 1996. J. Am. Acad. Dermatol. 37: 179-186 (1997)

82. Hughes B.R., et al.: Health education about sun and skin cancer: language, ideas and perceptions of young children. Br. J. Dermatol. 134: 624-629 (1996)

83. Boldeman C., et al.: Sunbed use in relation to pheno­type, erythema, sunscreen use and skin diseases: A ques­tionnaire survey among Swedish adolescents. Br. J. Der­matol. 135: 712-716 (1996)

84. Rossi J.S., et al.: Preventing skin cancer through be­havior change. Dermatol. Clin. 13: 613-622 (1995)

85. Marks R.: Melanoma prevention. Is it possible to change a population’s behavior in the sun? Pigment Cell Res. 7: 104-106 (1994)

86. Stender I.M.: Sun exposure and sunscreen use among sunbathers in Denmark. Acta Derm. Venereol. 76: 31-33 (1996)

87. Cambell H.S., Birdsell J.M.: Knowledge, benefits and sun protection behaviors of Alberta adults. Prev. Med. 23: 160-166 (1994)

88. Miller D.R., et al.: Melanoma awareness and self-ex­amination practices. J. Am. Acad. Dermatol. 34: 962-970 (1996)

89. Boldeman C., et al.: Sunbed use in Swedish urban adolescents related to behavioral characteristics. Prev. Med. 26: 114-119 (1997)

90. Miller D.: The public’s current knowledge, attitudes and behaviors regarding skin cancer prevention. National Con­ference to Develop a National skin cancer Agenda. Wash­ington, 8010 April, 1995

91. Melia J., Chamberlain I.: Melanoma awareness and sun exposure in Leicester. Br. J. Dermato. 134: 372 (1996)

92. Bourke J.F., et al.: Melanoma awareness and sun ex­posure in Leicester. Br. J. Dermatol. 132: 251-256 (1995)

93. Melia J., et al.: Investigating changes in awareness about cutaneus malignant melanoma in Britain, using the Omnibus Survey. Clin. Exp. Dermatol. 19: 375-379 (1994)

94. Healsmith M.F., et al.: Further experience of public education, for the early diagnosis of malignant melanoma in Leicestershire. Clin. Exp. Dermatol. 18: 396-400 (1993)

95. Higgins E.M., et al.: The application of the seven-point check-list in the assessment of benign pigmented lesions. Clin. Exp. Dermatol. 17: 313-315 (1992)

96. Dunkley M.P., Morris A.M.: Cutaneous malignant mela­noma: audit of the diagnostic process. Ann. Roy. Coll. Surg. Eng. 73: 248-252 (1991)

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση
Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ – ANNUAL SUBSCRIPTION
Γλώσσα Πλήρους Κειμένου –
Full Text Language
Ελληνικά – Greek
Παραγγελία – Αγορά –
Order – Buy
Ηλεκτρονική Μορφή: pdf (70 €) –
Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr
Έντυπη Μορφή (70 € + έξοδα αποστολής)
Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr

 

Προσθέστε στους σελιδοδείκτες το μόνιμο σύνδεσμο.

Τα σχόλια είναι απενεργοποιημένα.